Wockhardt Limited is a pharmaceutical and biotechnology company headquartered in Mumbai, India. Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is a research-based global health care enterprise with relevance in the fields of pharmaceuticals and biotechnology and with a chain of advanced super-specialty hospitals.
Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process, and techno-innovation within Wockhardt. At Wockhardt, we are looking for new ways of thinking, new ways of working, and new ways to touch people’s lives.
In the field of pharmaceuticals, Wockhardt is gaining a reputation in several parts of the world as a name to trust. Over the past 45 years, starting from its roots in India, Wockhardt has grown to a billion-dollar worldwide organization that today spans 14 countries in 5 continents. Over 8000 employees working in offices in our 12 manufacturing facilities, 3 research centers, and hospitals are completely dedicated to building an important trust in our products.
At Wockhardt, we draw our strength from the formidable foundation of trust built over the years through delivering quality products by continuously investing in R&D, modern manufacturing technologies, and contemporary processes. This enables us to deliver world-class quality products. At Wockhardt, we don’t merely formulate medicines, we formulate trust.
We believe that quality medicines begin with strong science and that the quality of our products is directly related to the integrity of our people. Over 525 quality control and quality assurance scientists guarantee that Wockhardt products’ 12 worldwide manufacturing facilities and 3 research centers meet the strict quality standards set by the FDA. Our world-class global R&D facilities are at the heart of Wockhardt’s pledge and commitment to deliver high-quality medicines at affordable prices and all are fully compliant with cGMP quality standards.
Wockhardt Limited created its US subsidiary, Wockhardt USA, in early 2004 with a modest portfolio of 3 FDA-approved generic products. In October 2007, Wockhardt Limited acquired Chicago-based Morton Grove Pharmaceuticals in order to expand Wockhardt’s product line in the United States. It is a 125,000-square-foot state-of-the-art facility.
Wockhardt USA LLC is leading the way in developing the most complete, high-quality line of generic oral solids, liquids, topicals, and injectables available in the United States. Wockhardt USA provides more than 258 NDCs spanning over 67 different product families. Wockhardt USA is also expanding its emerging branded products portfolio. We have been producing and distributing quality products in the US for over 9 years and have received over 110 ANDA approvals to date. Wockhardt USA has now become the largest overseas business for Wockhardt, contributing over 51% of the global revenues.
Key products in the Wockhardt USA product line include Azithromycin Tablets, Ceftriaxone Injection, Enalapril Tablets, Hydrocodone and Homatropine Syrup, Megestrol Acetate Oral Suspension, Metoprolol Succinate ER Tablets, Nystatin Oral Suspension, and Phenytoin Oral Suspension.
Wockhardt USA was the winner of the 2012 HDMA Diana Award in the category of Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of Less Than $100 Million and was the 2013 Second Merit Finalist in this same category.
For more information, please visit www.wockhardt.com